Werewolf Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Werewolf Therapeutics (HOWL).

Price Target Range — 9 Quarters

Analyst Consensus — 4 Analysts

1S.Buy

3Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$7Upside to Avg. PT+513.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Dec 19, 2025	HC Wainwright & Co.	Andres Y. Maldonado	PT Cut	Buy	$10→$4
Nov 18, 2025	B of A Securities	Jason Zemansky	PT Cut	Buy	$8→$7
Aug 25, 2025	B of A Securities	Jason Zemansky	PT Cut	Buy	$9→$8
Aug 21, 2025	JMP Securities	Reni J. Benjamin	PT Cut	Market Outperform	$4→$3
May 9, 2025	Wedbush	Robert Driscoll	PT Cut	Outperform	$8→$6
Mar 12, 2025	Wedbush	Robert Driscoll	Maintained	Outperform	$8
Mar 12, 2025	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
Jan 14, 2025	JMP Securities	Reni Benjamin	PT Cut	Market Outperform	$12→$4
Nov 19, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
Jul 2, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
Jun 26, 2024	JMP Securities	Reni Benjamin	Maintained	Market Outperform	$12
Jun 26, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
Jun 4, 2024	JMP Securities	Reni Benjamin	Maintained	Market Outperform	$12
Jun 3, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
May 24, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
May 6, 2024	JMP Securities	Reni Benjamin	Maintained	Market Outperform	$12
May 6, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
Apr 3, 2024	JMP Securities	Reni Benjamin	Initiate	Market Outperform	$12
Mar 7, 2024	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15
Nov 15, 2023	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$15

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $10 to $4.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $8 to $7.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8

B of A Securities analyst Jason Zemansky maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Buy and lowers the price target from $9 to $8.

Benzinga Newsdesk

PRO
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3

JMP Securities analyst Reni J. Benjamin maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Market Outperform and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

Wedbush analyst Robert Driscoll maintains Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and lowers the price target from $8 to $6.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

Wedbush analyst Robert Driscoll reiterates Werewolf Therapeutics (NASDAQ:HOWL) with a Outperform and maintains $8 price target.

Benzinga Newsdesk

Werewolf Therapeutics Inc

Werewolf Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8

PRO
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

PRO
Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

Werewolf Therapeutics Inc

Werewolf Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

PROB of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

PROB of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8

PROJMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3

PROWedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

PROWedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $4

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $7

PRO
B of A Securities Maintains Buy on Werewolf Therapeutics, Lowers Price Target to $8

PRO
JMP Securities Maintains Market Outperform on Werewolf Therapeutics, Lowers Price Target to $3

PRO
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6

PRO
Wedbush Reiterates Outperform on Werewolf Therapeutics, Maintains $8 Price Target